BrayF, FerlayJ, SoerjomataramI, SiegelRL, TorreLA, and JemalA. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 68, 394–424.
2.
DauresM, IdrissouM, JudesG, et al. (2018). A new metabolic gene signature in prostate cancer regulated by JMJD3 and EZH2. Oncotarget, 9, 23413–23425.
3.
DauresM, NgolloM, JudesG, et al. (2016). The JMJD3 histone demethylase and the EZH2 histone methyltransferase in prostate cancer. OMICS, 20, 123–125.
4.
MorozovVM, LiY, ClowersMM, and IshovAM. (2017). Inhibitor of H3K27 demethylase JMJD3/UTX GSK-J4 is a potential therapeutic option for castration resistant prostate cancer. Oncotarget, 8, 62131–62142.
5.
NgolloM, LebertA, DauresM, et al. (2017). Global analysis of H3K27me3 as an epigenetic marker in prostate cancer progression. BMC Cancer, 17, 261.
